President John Dramani Mahama has called on Indian companies to invest in Ghana’s pharmaceutical and vaccine manufacturing sectors as the government seeks to strengthen the country’s capacity to produce essential medicines locally.

He said Ghana is positioning itself to achieve greater health sovereignty by developing domestic pharmaceutical production and reducing reliance on imported health products.

Ghana to formally apply to join BRICS – Ablakwa

The engagement forms part of efforts by Ghana and India to deepen their longstanding relationship, with pharmaceutical manufacturing and health security emerging as key areas for future investment.

Speaking during a meeting with India’s External Affairs Minister on Tuesday, October 6, 2026, President Mahama said improving economic conditions were creating a more favourable environment for investors.

“Ghana’s economy is stable, inflation is declining and the cedi is holding its own, making Ghana an attractive destination for investment,” he said.

He cited Ghana’s partnership with Indian-linked Atlantic Life Sciences and local pharmaceutical company KinaPharma as an example of the type of investment cooperation his government wants to expand.

According to him, the partnership provides an opportunity to strengthen local vaccine production and build Ghana’s capacity to respond to future health emergencies.

“We want to use partnerships such as Atlantic Life Sciences and KinaPharma to expand our domestic vaccine manufacturing capacity,” President Mahama said.

He also urged more Indian businesses to consider Ghana as a base for pharmaceutical production and other investments, saying the country’s improving economic conditions provide a stronger foundation for such partnerships.



ANAS/MA

Foundries, Machines and Jet Engines: Ghana’s untapped engineering potential